Inactive Instrument

Stentys

Equities

STNT

FR0010949404

Medical Equipment, Supplies & Distribution

STENTYS Announces Consolidated Earnings Results for the Half-Year Ended June 30, 2016

September 15, 2016 at 01:50 pm EDT

STENTYS announced consolidated earnings results for the half-year ended June 30, 2016. For the period, the company’s revenues were EUR 3,644,000 against EUR 2,606,000 a year ago. Operating loss was EUR 4,034,000 against EUR 5,449,000 a year ago. Net loss was EUR 4,107,000 against EUR 5,421,000 a year ago.

Latest news about Stentys

Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-07	CI
STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020	20-05-15	CI
Stentys Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2019	19-10-14	CI
Stentys S.A. Announces Revenue Results for the First Quarter 2019	19-04-11	CI
Stentys Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-01	CI
Stentys S.A. Announces Audited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2018	19-01-10	CI
STENTYS S.A. Announces Consolidated Revenue Results for the Third Quarter and Nine Months Ended September 30, 2018	18-10-11	CI
STENTYS Announces Earnings Results for the Six Months Ended June 30, 2018	18-09-28	CI
STENTYS S.A. Announces Unaudited Consolidated Revenue Results for the Second Quarter and First Half of 2018	18-07-11	CI
STENTYS S.A. completed the acquisition of Minvasys.	18-04-29	CI
STENTYS S.A. Reports Revenue Results for the First Quarter Ended March 31, 2018	18-04-12	CI
STENTYS S.A. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2017	18-04-02	CI
STENTYS S.A. entered into an exclusive negotiations agreement to acquire Minvasys for €7.4 million.	18-01-29	CI
STENTYS S.A. Announces Unaudited Revenue Results for the Fourth Quarter and Full Year of 2017	18-01-08	CI
STENTYS S.A. Announces the Pre-Commercialization of SERPENTIS, Its New Latest-Generation of Active Stent	17-11-08	CI
STENTYS S.A. Announces Unaudited Revenue Results for the Third Quarter and First Nine Months Ended September 30, 2017	17-10-12	CI
STENTYS S.A. Announces Earnings Results for the Six Months Ended June 30, 2017	17-10-02	CI
STENTYS S.A. Announces Unaudited Revenue Results for the Second Quarter and First Half of 2017	17-07-12	CI
STENTYS S.A. cancelled the transaction announced on May 14, 2014	17-05-13	CI
STENTYS S.A. Announces Revenue Results for the First Quarter Ended March 31, 2017	17-04-24	CI
STENTYS S.A. Announces Executive Changes	17-03-21	CI
STENTYS S.A. Reports Earnings Results for the Year Ended December 31, 2016	17-03-21	CI
STENTYS Reports Revenue Results for the Fourth Quarter and Full Year of 2016	17-01-12	CI
STENTYS Announces Revenue Results for the Third Quarter and Nine Months Ended September 30, 2016	16-10-12	CI
STENTYS Announces Consolidated Earnings Results for the Half-Year Ended June 30, 2016	16-09-15	CI

Chart Stentys

Duration

Period

More charts

Company Profile

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's institutional shareholders are Sofinnova Partners, Credit Agricole Private Equity and Scottish Equity Partners. In June 2014, it acquired Cappella Peel Away Inc.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.54%	187B
MEDTRONIC PLC	-1.85%	106B
BECTON, DICKINSON AND COMPANY	-4.26%	66.9B
DEXCOM, INC.	+1.39%	49.45B
CENCORA, INC.	+16.82%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution